二肽基肽酶4抑制剂对2型糖尿病患者心血管疾病的影响  

Effect of DPP-4 inhibitors on cardiovascular disease in patients with type 2 diabetes mellitus

作　　者：马慧梅 公丕云 董建军[1] MA Huimei;GONG Piyun;DONG Jianjun(Department of Endocrinology,Qilu Hospital of Shandong University,Jinan 250012,China)

机构地区：[1]山东大学齐鲁医院内分泌科,济南250012

出　　处：《中国糖尿病杂志》2020年第3期237-240,共4页Chinese Journal of Diabetes

摘　　要：二肽基肽酶4抑制剂(DPP-4i)是一种新型口服降糖药,在糖尿病联合治疗中优势明显,是近年来使用率增长最快的口服降糖药物.DPP-4i在心血管死亡、心肌梗死、卒中事件中不增加心血管复合终点的风险,其作用机制可能是上调基质细胞衍生因子1α、减少可溶性细胞间黏附分子1表达水平,以降低炎症和心肌纤维化作用.不同DPP-4i对心力衰竭的影响不同,肾脏钠/氢交换因子3可能是其潜在的保护靶点.近年来,利格列汀以其独特的优势,优先在DKD患者中使用.Dipeptidyl peptidase 4 inhibitor(DPP-4i)is a new type of oral hypoglycemic agent. The utilization of DPP-4i is growing rapidly in recent year with advantages in the combination therapy of diabetes.DPP-4i does not increase the risk of cardiovascular compound endpoints in cardiovascular death,myocardial infarction and stroke events. The mechanism may be up-regulating stromal cell-derived factor 1(SDF-1α)and inhibiting the expression of soluble intercellular adhesion molecule 1 to reduce inflammation and fibrosis.Different DPP-4i have different effects on heart failure,of which,renal sodium hydrogen exchanger 3 may be a potential protection target. With its unique advantages,linagliptin is preferred for patients with diabetic kidney disease.

关 键 词：糖尿病 2型 二肽基肽酶4抑制剂 心血管疾病 机制 

分 类 号：R587.2[医药卫生—内分泌] R54[医药卫生—内科学]